ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of ColdZyme® on Experimentally Induced Common Cold. (COLDPREVII)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02479750
Recruitment Status : Completed
First Posted : June 24, 2015
Last Update Posted : February 7, 2019
Sponsor:
Information provided by (Responsible Party):
Enzymatica AB

Brief Summary:
This study evaluates the performance of ColdZyme® mouth spray on prevention of common cold symptoms on experimentally induced rhinovirus upper respiratory tract infection in healthy volunteers. Half of participants will receive ColdZyme® mouth spray while the other half will receive placebo.

Condition or disease Intervention/treatment Phase
Common Cold Device: ColdZyme® mouth spray Device: Placebo Not Applicable

Detailed Description:
88 subjects will be inoculated with rhinovirus 16 via the nasal route. The subjects will be randomized 1:1 to ColdZyme® or placebo. Treatment (6 doses per day) will be applied for 11 days from the day of inoculation. The subjects will visit the investigational clinic on 6 occasions. During these visits the subjects will leave nasal (lavage) and pharyngeal (swab) samples for quantification of virus replication. All subjects will have a diary for scoring of cold symptoms.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 88 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Evaluation of ColdZyme® on Experimentally Induced Common Cold. -A Double-blind, Randomized, Placebo-controlled Study in Healthy Volunteers.
Actual Study Start Date : March 23, 2016
Actual Primary Completion Date : July 25, 2016
Actual Study Completion Date : July 25, 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Common Cold

Arm Intervention/treatment
Experimental: ColdZyme
ColdZyme® mouth spray liquid. Treatment (6 doses per day) will be applied for 11 days from the day of inoculation.
Device: ColdZyme® mouth spray
Placebo Comparator: Placebo
Sugar based mouth spray liquid manufactured to mimic ColdZyme® mouth spray. Treatment (6 doses per day) will be applied for 11 days from the day of inoculation.
Device: Placebo



Primary Outcome Measures :
  1. Reduction of virus load [ Time Frame: 7 days ]
    The primary objective is to investigate the protective effect of ColdZyme® mouth spray against infection in the oropharynx by common cold virus (rhinovirus 16) in vivo in relation to placebo


Secondary Outcome Measures :
  1. Reduce the number of days with common cold symptoms [ Time Frame: 11 days ]
  2. Reduce the number of days with virus present in oropharynx [ Time Frame: 11 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   16 Years to 70 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male or female subjects between 16-70 years. The investigator judges the definition of healthy by detailed medical history and physical examination.
  • Females of childbearing potential: shall use reliable method of birth control. Reliable methods are hormonal contraceptives (combination pills, injections or implants), intrauterine device, condom or declared absence of sexual contact. Post-menopausal woman is defined as absence of menstrual discharge for at least two years.
  • Signed informed consent form prior to any study-related procedures.
  • Willingness and ability to adhere to the prohibitions and restrictions specified in this protocol.
  • Perceived to have had at least one cold per year

Exclusion Criteria:

  • Smoker, during the last 12 months
  • Any cold symptom within the last month such as sore throat, sneezing, rhinorrhoea, malaise, nasal obstruction or cough.
  • Presence (at screening) of serum rhinovirus 16 neutralising antibody titers at greater than or equal to one in two dilution.
  • Active allergic rhinitis, asthma or chronic obstructive pulmonary disease during study period.
  • Nasal disease, e.g. nasal polyposis, significant septal deviation, chronic rhinosinusitis, etc.
  • Females: Pregnant, breast-feeding or intentions to become pregnant during the study.
  • Evidence or history of drug or alcohol abuse.
  • Use of any prescribed or non-prescribed medication (except for contraceptives, paracetamol and ibuprofen) within 2 weeks prior to the first administration of investigational product.
  • Use of any over the counter cold prophylaxis products such as ColdZyme®, C-vitamins, zinc or Echinacea within 1 month prior to the first administration of investigational product.
  • Participation in other clinical trial with medical investigational product within 60 days prior to the first administration of investigational product.
  • Hypersensitivity/allergy to any of the device ingredients
  • Individuals with close contact to at risk patient group:
  • infants (less than 6 months);
  • the extremely elderly or infirm;
  • pregnant women;
  • patients with severe lung disease (asthma/cystic fibrosis (CF)/COPD);
  • patients with immunosuppression.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02479750


Locations
United Kingdom
National Heart and Lung Institute, Imperial College
London, United Kingdom, W2 1PG
Sponsors and Collaborators
Enzymatica AB
Investigators
Principal Investigator: Patrick Mallia, MD NHLI, Imperial College

Responsible Party: Enzymatica AB
ClinicalTrials.gov Identifier: NCT02479750     History of Changes
Other Study ID Numbers: ENZY-002
First Posted: June 24, 2015    Key Record Dates
Last Update Posted: February 7, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Common Cold
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases